RT Journal Article
SR Electronic
A1 Sylvester, Bruce
T1 Promise and Problems Emerge for Oral Investigative Factor Xa Drug in Treating Acute Coronary Syndrome
JF MD Conference Express
YR 2008
FD SAGE Publications
VO 8
IS 6
SP 22
OP 23
DO 10.1177/155989770800800613
UL http://mdc.sagepub.com/content/8/6/22.abstract
AB Treatment with investigative apixaban, an oral factor Xa inhibitor, shows promise as add-on protection against recurrent ischemic cardiovascular events among acute coronary syndrome patients who already are on standard antiplatelet therapy, including aspirin and clopidogrel. But dose-dependent bleeding remains an unresolved problem. This article discusses the Phase 2, Placebo-Controlled, Randomized, Double-Blind, Parallel Arm, Dose-Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome [APPRAISE-1; NCT00313300] trial.